Association of gene polymorphisms in thyroid function-related genes with differentiated thyroid cancer risk and post thyroidectomy l-thyroxine suppressive dose requirements

摘要: Patients with differentiated thyroid cancer (DTC) are usually managed total thyroidectomy and subsequent radioiodine ablation of the remnant tissue. Since these patients become athyrotic, L-throxine (L-T4) therapy is required for life, in order to replace hormones also suppress endogenous stimulating hormone (TSH) which may have a growth-promoting effect on any residual cells. The approximate dose achieve this suppression about 2 g/kg. However, there wide variation between their L-T4 requirement. Although factors such as timing dose, compliance, weight age play important roles, genetic thought be variability. Therefore, aims study identify evaluate association polymorphisms six genes [(iodothyronine deiodinases (DIO) 1, 3, paired box gene 8 (PAX8), subunit β (TSHβ), sodium iodide symporter (NIS)], involved metabolic functional pathways DTC risk